All the news Showing 10 of 46 articles from: Access to medicines & diagnosticsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Public-sector hepatitis C treatment programmes expanding in lower- and middle-income countries Keith Alcorn / 08 January 2021 Public-sector hepatitis C treatment programmes have cured tens of thousands of people in lower- and lower-middle-income countries with the aid of low-cost direct-acting antivirals and diagnostics, a simplified approach to treatment and large-scale ... 2.5 million people in Africa need urgent hepatitis B treatment Keith Alcorn / 09 December 2020 Around 2.5 million people with hepatitis B in sub-Saharan Africa already have cirrhosis and need immediate antiviral treatment, a systematic review of published studies reports this month in the journal Liver International. Approximately ... Cameroon study shows hepatitis C treatment is feasible, highly effective in sub-Saharan Africa Keith Alcorn / 23 June 2020 High cure rates for hepatitis C can be achieved in Cameroon but the cost of treatment remains out of reach for all but the wealthiest, findings from a demonstration study of direct-acting antiviral ... Voluntary licensing of hepatitis C drugs has led to more people on treatment Keith Alcorn / 28 August 2019 Voluntary licensing of hepatitis C treatments to generic drug manufacturers for sale in lower- and middle-income countries has increased the number of people treated by approximately 70 per thousand people diagnosed with hepatitis ... Tackling HIV and hepatitis C in Europe: towards minimum standards Gus Cairns / 11 February 2019 Despite the huge disparities in care that were highlighted, last week's Standard of Care for HIV and Coinfections in Europe meeting in Bucharest featured discussions that could form the basis of a European-wide ... Generic DAAs achieve excellent cure rates in Egypt matching those of branded drugs at a fraction of the cost Michael Carter / 01 February 2019 Generic direct-acting antivirals (DAAs) are just as effective and safe as their branded equivalents for the treatment of chronic hepatitis C virus (HCV) infection, according to Egyptian research published in Liver International. Generics achieved ... Barriers to HCV treatment access from the drug user's point of view: stigma, complex lives and damaged veins Keith Alcorn / 16 January 2019 Despite access to hepatitis C treatment, many people who inject drugs still perceive numerous barriers to starting treatment, including the attitudes of healthcare workers, the difficulty of juggling treatment with competing demands, a ... Lancet commission sets agenda for the elimination of viral hepatitis Keith Alcorn / 10 January 2019 Viral hepatitis leads to around 1.3 million deaths a year, approximately 257 million people are living with hepatitis B virus (HBV) and 71 million with hepatitis C virus (HCV). Viral hepatitis ... Access to testing and treatment for hepatitis C in European prisons must improve Keith Alcorn / 30 May 2018 Lack of access to hepatitis C treatment and prevention in European prisons is a public health emergency and risks breaching international agreements on the avoidance of inhumane and degrading conditions, ... HCV treatment feasible and effective in sub-Saharan Africa Keith Alcorn / 17 April 2018 A 12-week course of sofosbuvir/ledipasvir proved highly effective in a sub-Saharan African setting, results of a study carried out in Rwanda show. The findings were presented on Friday at the ... ← First12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive